ReviewBiomedicines2022
The End of "One Size Fits All" Sepsis Therapies: Toward an Individualized Approach.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Assessing Monoclonal and Polyclonal Antibodies in Sepsis and Septic Shock: A Systematic Review of Efficacy and Safety.International journal of molecular sciences · 2025Pooled it
- Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cell Therapy in Preclinical Models of Sepsis: A Systematic Review and Meta-analysis.Stem cells translational medicine · 2024Pooled it
- Clinical subphenotypes in septic patients with new-onset atrial fibrillation: validation and parsimonious classifier model development.BMC medical informatics and decision making · 2026Article
- Immunomodulatory Empty/Hollow Nanoparticles as Potential Therapeutic Strategies for Septic Shock.Biomedicines · 2026Review
- Host-directed immune therapies: a second front in the battle against sepsis.The Journal of clinical investigation · 2026Review
- Managing sepsis in the era of precision medicine: a narrative review.Acute and critical care · 2026Article
- Secreted phospholipase PLA2G5 acts as a hemolytic factor in sepsis.The Journal of clinical investigation · 2026Article
- CX3CR1-mediated immune networks in sepsis: implications for precision therapy.Cell death discovery · 2026Review
- Pathogen characteristics are key determinants of distinct host response phenotypes of sepsis.The Journal of clinical investigation · 2026Observational
- Advanced Age in Mice Exacerbates Sepsis-Induced Inflammation, Vascular Permeability, and Multi-Organ Dysfunction.Shock (Augusta, Ga.) · 2026Article
- Artificial intelligence for sepsis management in the emergency department.BMC infectious diseases · 2026Review
- Targeting the Gut in Sepsis: Therapeutic Potential of Medical Gases.Biomolecules · 2026Review
- Breaking the Stalemate: Advancing Sepsis Therapeutics Beyond Supportive Care.Public health reports (Washington, D.C. : 1974) · 2026Article
- Data-driven spatial-temporal framework for exploring the heterogeneity and temporality of sepsis.Chinese medical journal · 2026Review
- Emerging Roles and Possible Therapeutic Applications of Arachidonic Acid Metabolites in Sepsis and Sepsis-Associated Organ Dysfunction.Drug design, development and therapy · 2026Review
- Assessment of soluble PD-L1 in septic shock in relation to immunosuppressive phenotypes.Annals of intensive care · 2026Article
- Macrophage reprogramming and functional plasticity in sepsis.Frontiers in immunology · 2026Review
- The International, Prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: Interim Results in Patients with Septic Shock.Annals of intensive care · 2026Article
- Association of oXirisJournal of personalized medicine · 2025Article
- Association of Modifiable Lifestyle and Metabolic Factors With the Risk of Developing Sepsis: 2-Sample Mendelian Randomized Study.Interactive journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to an infection, remains a major challenge for clinicians and trialists. Despite decades of research and multiple randomized clinical trials, a specific therapeutic for sepsis is not available. The evaluation of therapeutics targeting components of host response anomalies in patients with sepsis has been complicated by the inability to identify those in this very heterogeneous population who are more likely to benefit from a specific intervention. Additionally, multiple and diverse host response aberrations often co-exist in sepsis, and knowledge of which dysregulated biological organ system or pathway drives sepsis-induced pathology in an individual patient is limited, further complicating the development of effective therapies. Here, we discuss the drawbacks of previous attempts to develop sepsis therapeutics and delineate a future wherein interventions will be based on the host response profile of a patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.